At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 214 enrolled
Drug / intervention
VIB7734 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
In Brief
A Phase 2 clinical trial evaluating VIB7734 and Placebo for Lupus Erythematosus, Systemic. Completed, enrolled 214 participants across 67 sites in 11 countries.
Detailed Summary
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus in approximately 195 participants. The study duration will be 48 weeks, with a safety follow-up through week 56.There will be 3 parallel arms - 2 active treatment and 1 placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLupus Erythematosus, Systemic
CountriesArgentina, Greece, India, Mexico, Poland, Russia, Serbia, Spain, Taiwan, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartMay 2021
First PostedJun 2021
Primary CompletionMay 2023
Study CompletionJun 2023
TodayJul 2026
First PostedJun 14, 2021
Enrollment StartMay 28, 2021
Primary CompletionMay 16, 2023
Study CompletionJun 9, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.0 years ago
Interventions
VIB7734drug
VIB7734
Placeboother
Placebo